Venetoclax — Drug Intelligence | 116 EU Trials

Filter these 116 trials by condition, phase, country and more.

Open in Search →

116 Registered trials

46 Recruiting

60 Completed trials

69 Sponsors

24 Countries

Phase III

Phase II

Phase I/II

Phase III: 33 Phase II/III: 4 Phase II: 48 Phase I/II: 23 Phase IV: 3 Phase I (Other): 1 Phase I (FiH): 4

Oversight events:

6 serious breaches 6 temporary halts 5 urgent safety measures 1 unexpected event 3 corrective measures across 11 trials

View oversight register →

Indications tested

Acute myeloid leukaemia 14 Myelodysplastic syndrome 7 Chronic lymphocytic leukaemia 5 B-cell small lymphocytic lymphoma 3 Mantle cell lymphoma 2 Chronic lymphocytic leukaemia recurrent 2 Chronic myelomonocytic leukaemia 2 Blastic plasmacytoid dendritic cell neoplasia 1 Chronic myeloid leukaemia 1 Non-Hodgkin's lymphoma 1 Renal cell carcinoma 1 Triple negative breast cancer 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 13 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 7 BeOne Medicines AG 5 Fondazione Gimema Franco Mandelli Onlus 4 University Of Cologne 4 AstraZeneca AB 3 F. Hoffmann-La Roche AG 3 Groupe Francophone Des Myelodysplasies 3 Janssen - Cilag International 3 Ospedale San Raffaele S.r.l. 3 Technische Universitat Dresden 3 Haemato Oncology Foundation For Adults Netherlands 2

All trials — page 5

116 total

A multicentre clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax… Ended

2024-519275-26-00 Phase I/II 1 country Fundacion PETHEMA
Venetoclax after TKI to target persisting stem cells in CML Ended

2024-516214-38-00 Phase II 1 country Friedrich-Schiller-Universitaet Jena
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen… Ended

2022-501537-23-00 Phase II 1 country University of Leipzig
Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1) Ended

2024-510939-21-00 Phase II 1 country Syros Pharmaceuticals Inc.
VEN-DEC GITMO Study Ended

2024-518792-54-00 Phase II 1 country Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche…
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refract… Ended

2024-514948-89-00 Phase I/II 1 country Klinikum der Universitaet Muenchen AöR
A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in … Ended

2024-515424-36-00 Phase II 2 countries Takeda Development Center Americas Inc.
Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended

2023-507222-17-00 Phase III 7 countries AbbVie Deutschland GmbH & Co. KG
Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended

2023-507221-42-00 Phase III 7 countries AbbVie Deutschland GmbH & Co. KG
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri… Ended

2023-504036-17-00 Phase III 3 countries F. Hoffmann-La Roche AG
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 Phase I/II 1 country Technische Universitaet Dresden
A Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformatio… Ended

2024-516675-32-00 Phase II 1 country ASST Grande Ospedale Metropolitano Niguarda
Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended

2024-511533-35-00 Phase II 1 country Fondazione Italiana Linfomi Ets
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia … Ended

2024-513630-37-00 Phase III 1 country AbbVie Deutschland GmbH & Co. KG
A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who ar… Ended

2024-513631-25-00 Phase III 6 countries AbbVie Deutschland GmbH & Co. KG
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended

2023-510557-42-00 Phase II 6 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Phase II 1 country Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs) Ended

2024-516750-21-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Phase III 11 countries F. Hoffmann-La Roche AG
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized … Ended

2023-509092-16-00 Phase II 1 country Akershus University Hospital

Showing 97–116 of 116 trials

← All drugs A–Z